| Long non-coding RNA H19 and cancer: A competing endogenous RNA |
26 |
| Colorectal cancer cell-derived exosomes containing miR-10b regulate fibroblast cells via the PI3K/Akt pathway |
21 |
| Exosomes of glioma cells deliver miR-148a to promote proliferation and metastasis of glioblastoma via targeting CADM1 |
18 |
| Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks |
15 |
| Descriptive epidemiology of cancer in metropolitan France: Incidence, survival and prevalence |
9 |
| Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma |
9 |
| Management of cytokine release syndrome in adult and pediatric patients undergoing CAR-T cell therapy for hematological malignancies: Recommendation of the French Society of Bone Marrow and cellular Therapy (SFGM-TC) |
8 |
| MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors |
7 |
| PTBP1 promotes tumorigenesis by regulating apoptosis and cell cycle in colon cancer |
7 |
| Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA- anti-PD-1 and anti-PD-L1 antibodies in cancer treatment |
7 |
| Methylation analysis for multiple gene promoters in non-small cell lung cancers in high indoor air pollution region in China |
6 |
| Update of the recommendations of good clinical practice for the use of PET in oncology |
6 |
| Knockdown of miR-299-Sp inhibits the progression of hepatocellular carcinoma by targeting SIAH1 |
6 |
| Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors? |
5 |
| PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer |
5 |
| Obesity and Cancer |
5 |
| Precision medicine and bladder cancer heterogeneity |
5 |
| Psychological impact of ostomy on the quality of life of colorectal cancer patients: Role of body image, self-esteem and anxiety |
5 |
| Epidemiology of pancreatic cancer |
5 |
| Paraneoplastic syndromes in cancers of unknown primary: An unknown field for oncologists |
4 |
| Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency |
4 |
| The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition |
4 |
| Management of uveal melanomas, guidelines for oncologists |
4 |
| Thyroid carcinoma on struma ovarii: Diagnosis and treatment |
3 |
| High-risk neuroblastoma treatment strategy: The experience of the SIOPEN group |
3 |
| Aspirin and colorectal cancer |
3 |
| 5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer |
3 |
| WHO classification of head and neck tumours 2017: Main novelties and update of diagnostic methods |
3 |
| Evidence of slight improvement in five-year survival in non-small-cell lung cancer over the last 10 years: Results of the French KBP-CPHG real-world studies |
3 |
| Prediction of chemotherapy response in primary osteosarcoma using the machine learning technique on radiomic data |
3 |
| Impact of a coordinated regional organization to secure the management of patients on oral anticancer drugs: CHIMORAL, a comparative trial |
3 |
| Diagnostic and treatment pitfalls and guidelines for variants of squamous cell carcinomas of the head and neck: on behalf of the REFCOR Parmi |
3 |
| Immunotherapy-induced endocrinopathies: Insights from the 2018 French Endocrine Society Guidelines |
2 |
| Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists |
2 |
| DICER1 constitutional pathogenic variant syndrome: Where are we in 2019? |
2 |
| Radiation induced optic neuropathy: Does treatment modality influence the risk? |
2 |
| Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa |
2 |
| Myocarditis: Uncommon but severe toxicity of immune checkpoint inhibitors |
2 |
| Consumption of processed and pickled food and esophageal cancer risk: A systematic review and meta-analysis |
2 |
| Gut microbiota: What impact on colorectal carcinogenesis and treatment? |
2 |
| Fertility preservation in oncology |
2 |
| Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs |
2 |
| Dermatofibrosarcoma: Management |
2 |
| Some important breakthroughs in oncology and hematology in 2018: A selection by the editorial board of Bulletin du Cancer |
2 |
| Specific immunotherapies in the treatment of cancers |
2 |
| Update in treatment for Merkel Cell Carcinoma and clinical practice guide |
2 |
| Pretreatment blood neutrophil/lymphocyte ratio is associated with metastasis and predicts survival in patients with pancreatic cancer |
2 |
| Atezolizumab (Tecentriq (R)): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma |
2 |
| Body image disorder in 100 Tunisian female breast cancer patients |
2 |
| Neuroendocrine tumors of the breast: Myth or reality? A systematic review |
2 |
